drugset / Trial / NCT02141477
Omacetaxine and Decitabine in Acute Myelogenous Leukemia (AML) and Myelodysplastic Syndrome (MDS)
NaSingle-groupOpen-labelTreatment
Summary
This clinical research study is made up of 2 phases. The goal of Phase 1 of the study is to test the safety of the combination of omacetaxine and decitabine and to find the best dose to give to future patients. The goal of Phase 2 of the study is to learn if this dose can help to control AML and/or MDS. The safety will then continue to be studied.
Timeline
- Start
- 2015-05-06
- Primary completion
- 2017-06-22
- Completion
- 2017-06-22
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Decitabine | Small molecule | 20 mg/m2 | Intravenous |
| Subject | Omacetaxine | Unknown | 1.25 mg/m2 | Subcutaneous |